Literature DB >> 34815247

Novel MYO5B mutation in microvillous inclusion disease of Syrian ancestry.

Kamal Hassan1, Amal Robay2, Aljazi Al-Maraghi3, Nuha Nimeri1, Asmaa Basheer Azzam1, Alya Al Shakaki2, Eman Hamid1, Ronald G Crystal4, Khalid A Fakhro2,3.   

Abstract

Microvillus inclusion disease (MVID) is a rare autosomal recessive condition characterized by a lack of microvilli on the surface of enterocytes, resulting in severe, life-threatening diarrhea that could lead to mortality within the first year of life. We identify two unrelated families, each with one child presenting with severe MVID from birth. Using trio whole-exome sequencing, we observed that the two families share a novel nonsense variant (Glu1589*) in the MYO5B gene, a type Vb myosin motor protein in which rare damaging mutations were previously described to cause MVID. This founder mutation was very rare in public databases and is likely specific to patients of Syrian ancestry. We present a detailed account of both patients' clinical histories to fully characterize the effect of this variant and expand the genotype-phenotype databases for MVID patients from the Middle East.
© 2022 Hassan et al.; Published by Cold Spring Harbor Laboratory Press.

Entities:  

Keywords:  volvulus

Mesh:

Substances:

Year:  2022        PMID: 34815247      PMCID: PMC8958910          DOI: 10.1101/mcs.a006103

Source DB:  PubMed          Journal:  Cold Spring Harb Mol Case Stud        ISSN: 2373-2873


INTRODUCTION

Microvillus inclusion disease (MVID; MIM # 251850), also known as congenital microvillus atrophy, was first described by Davidson et al. (1978). It is a rare autosomal recessive disease that presents with an intractable life-threatening watery diarrhea either within the first days of life (early-onset form) or at several months of life (late-onset form) (Ruemmele et al. 2006). The hallmarks of MVID are a lack of microvilli on the surface of villous enterocytes, the occurrence of microvillous inclusions, and the cytoplasmic accumulation of periodic acid–Schiff-positive vesicles (Davidson et al. 1978; Cutz et al. 1989; Ruemmele et al. 2010). Müller et al. (2008) showed that mutations in MYO5B (MIM # 606540), encoding the unconventional type Vb myosin motor protein, were associated with MVID in an extended Turkish kindred. Since then, more mutations were described in different populations (Dhekne et al. 2018). In this report, we describe a novel mutation in two unrelated Syrian patients with MVID.

RESULTS

Patient 1 (MVID-1)

A Syrian girl was born at 36-wk gestation to consanguineous parents originally from the eastern part of Syria. The mother was 22-yr-old, gravida 7, para 3. Her previous three daughters died in Syria at 7, 10, and 30 d of age, following intractable diarrhea of unknown diagnosis. Since the first day of life, the patient was started on breast milk but developed severe diarrhea leading to dehydration and acidosis. Changing the feeds to elemental formula (Neocene LCP, SHS) made no difference to her symptoms. The oral feeding was discontinued and she was started on total parenteral nutrition (TPN). Examinations of other organ involvement such as cardiovascular system, lungs, and kidney were unremarkable. Nonetheless, the patient had frequent hospital admissions because of dehydration and sepsis. During her disease, the patient also developed cholestasis with pruritus because of prolonged TPN use. Her serum bile acids and liver enzymes were high, and she was treated with ursodeoxycholic acid to improve cholestasis. Investigations for infection, cystic fibrosis, metabolic, and immunodeficiency disorders were all unremarkable. The patient was also seen and investigated extensively by the endocrinology team to rule out congenital adrenal hyperplasia (CAH) as a cause of diarrhea. Histological analysis of multiple gastrointestinal biopsies was obtained postendoscopy. In this patient, the histopathology of the duodenal mucosa showed subtotal and total villous atrophy with slightly elongated crypts. There were no granuloma, dysplasia, nor malignancies seen. A vacuolated apical cytoplasm was noted in hematoxylin and eosin (H&E) sections and highlighted by special stains (PAS) that showed cytoplasmic staining of the luminal aspect of enterocytes. Immunohistochemical staining for polyclonal anti-CEA, CD10 stains illustrated microvillus abnormalities including patchy normal band-like brush border with the internalization of brush border in the cytoplasm. The overall morphological and immunohistochemical appearances were broadly compatible with the clinical impression of MVID. Microscopic examination of fragments of the large bowel mucosa and the stomach revealed no significant histological abnormality. Whole-exome sequence (WES) identified a novel mutation in the MYO5B gene. Her clinical course and outcome are summarized in Table 1.
Table 1.

Demographic and clinical characteristics of the two patients with microvillus inclusion disease (MVID)

ParameterMVID-1MVID-2
SexFemaleMale
AncestrySyrian, Eastern regionSyrian, Western region
ConsanguinityYesYes
MYO5B mutationc.G4765TGlu1589*: stop-gainedc.G4765Tp.GLlu1589*: stop-gained
PresentationEarly-onset severe diarrheaEarly-onset severe diarrhea
Extraintestinal manifestationsMild developmental delay; cholestasis with pruritus, low γ-glutamyl transferase, and high serum bile acidsGlobal developmental delay; intractable myoclonic seizures; medullary nephrocalcinosis; recurrent urinary tract infection
OutcomeDied at 19 mo following H1N1 infectionRelocated to a neighboring country at 17 mo and died at 23 mo of age
Demographic and clinical characteristics of the two patients with microvillus inclusion disease (MVID) Nine months later, the mother became pregnant. Amniocentesis at 12 wk for genetic testing for the MYO5B mutation was positive; the parents chose to abort the baby. Six months later, the mother became pregnant again. Amniocentesis done at 13-wk gestation was negative, and 6 mo later the mother gave birth to a healthy baby.

Patient 2 (MVID-2)

A Syrian boy was born at 34-wk gestation to consanguineous parents originally from the western part of Syria. This was their first baby and there was no history of abortion. The patient developed severe diarrhea associated with acidosis. Changing the feeds from breast milk to elemental formula (Neocate LCP, SHS) made no difference and he had to be started on TPN. Investigations for infection, cystic fibrosis, metabolic, and immunodeficiency disorders were all unremarkable. At the age of 6 mo, the patient developed acute disseminated encephalomyelitis (ADEM)—an immune-mediated inflammatory demyelinating condition that predominately affects the white matter of the brain and spinal cord. Convulsive seizures occur around the onset of ADEM in as many as 35% of cases as well as long tract signs such as clonus and increased muscle stretch reflexes that can occur in as many as 85% of cases. ADEM was only present in MVID-2. Patient 2 also developed cholestasis with pruritis, in which liver enzymes level and serum bile acid levels were elevated most likely because of the prolonged TPN use. This was also present in Patient 1. Investigation of sections from the small intestine showed loss of villous architecture with mild crypt hyperplasia. There also appeared to be “internalization” with a patchy distribution of the brush border evident in PAS stain as well as on CD10 (immunohistochemical [IHC] stains done with appropriate controls). Both the villous atrophy and “internalization of brush border” were suggestive of MVID. Investigation with WES revealed the same mutation as in Patient 1. Trials of even small amounts of different formulae caused significant diarrhea and electrolyte disturbances. His clinical course is summarized in Table 1. At 23 mo of age, the child died.

DISCUSSION

Geographically, there is a relatively high prevalence of MVID in the Mediterranean region—almost 50% of all the patients with reported geographical information (Halac et al. 2011; van der Velde et al. 2013). There have been no reported MVID cases from Syria, and the two patients reported in this report are the first MVID cases of Syrian ancestry. Although both families were not closely related and hailed from two different areas in Syria, they both carried the same MYO5B novel mutation Glu1589*. Because this variant is globally very rare, its presence in two families from the same country suggests that this is a geographically specific founder mutation. As expected from the predicted loss-of-function effect on the protein, the clinical presentation showed severe disease in both patients who could hardly tolerate oral feeding and were completely dependent on TPN. Both patients had developmental delays, consistent with previously reported MVID cases (Phillips and Schmitz 1992; Halac et al. 2011). Patient 2 also developed intractable myoclonic seizures that needed three anti-epileptic medications to control; this complication was never reported in previous MVID cases. Patient 1 developed pruritus and cholestasis consistent with progressive familial intrahepatic cholestasis-like illness, which has been previously described in MVID (Girard et al. 2014). It is unclear to what extent these extra-intestinal phenotypes may be iatrogenic or linked to the MYO5B mutations, and patient-specific disease models are eagerly awaited (van der Velde et al. 2013). In conclusion, this is the first report of MVID in Syrian patients. The rarity of this mutation in public databases yet being homozygous in two unrelated Syrian patients suggests this is a Syrian founder mutation. The utility of identifying causative mutations within a family allows for reliable genetic counseling, prenatal screening, and embryo selection by preimplantation genetic testing.

METHODS

WES of proband and parents was done using Agilent's SureSelect v5 platform and sequenced on Illumina's HiSeq 2000. Reads were mapped to the human reference genome GRCh37/hg19 using BWA 0.5.9 and variants called using GATK Best Practices (as described in Fakhro et al. 2019). Each exome was verified to have a minimum average depth of 50× (Tables 2 and 3). Causative variants were identified by searching for high-quality (quality score >100), rare (minor allele frequency <0.1%), recessive mutations with a predicted pathogenic impact (loss-of-function mutation, and/or GERP score > 2, PolyPhen score > 0.9, CADD score > 20). Candidate variants surviving this filtration were manually evaluated for genes with reasonable implications in disease by the literature and database searches.
Table 2.

Variant table

GeneChrHGVS DNA referenceHGVS protein referenceVariant typePredicted effectdbSNP/dbVar IDGenotypeClinVar IDParent of origin
MYO5B 18c.G4765Tp.Glu1589*SNVSubstitutionrs762039116HomozygousVCV000620180Both heterozygous
Table 3.

Sequencing coverage table

SampleMean depth of coverage
MVID-1 Index78.2
MVID-1 Mother67.3
MVID-1 Father54.4
MVID-2 Index93.3
MVID-2 Mother64.9
MVID-2 Father83.1
Average depth73.5
Variant table Sequencing coverage table

Genetic Testing

The exomes of all the available family members were sequenced to a minimum depth of 54× (mean depth 73.5×) and variant calls according to best practices. Within the framework of reported consanguinity, variants were filtered based on being recessive (homozygous in the index and heterozygous in the parents), rare, and predicted damaging by a range of evolutionary scores. Both sets of patients were found to have the nonsense mutation p.Glu1589* in the MYO5B gene (Figs. 1 and 2). This protein-truncating mutation has a reported global allele frequency of <0.001% and is predicted to cause loss of gene function.
Figure 1.

Family diagrams for the two patients identified with microvillus inclusion disease (MVID). In both cases, the index case (black arrow pointing to the sequenced index) and parents were collected and sequenced (thick boxes/circles). Shown also for family 1 are the four previous siblings born with MVID who died perinatally.

Figure 2.

Sanger sequencing trace showing the glutamate to stop codon mutation at amino acid position 1589 in the MYO5B gene. This mutation is caused by a mutation from guanine (G) to thymine (T) at position 4765.

Family diagrams for the two patients identified with microvillus inclusion disease (MVID). In both cases, the index case (black arrow pointing to the sequenced index) and parents were collected and sequenced (thick boxes/circles). Shown also for family 1 are the four previous siblings born with MVID who died perinatally. Sanger sequencing trace showing the glutamate to stop codon mutation at amino acid position 1589 in the MYO5B gene. This mutation is caused by a mutation from guanine (G) to thymine (T) at position 4765.

ADDITIONAL INFORMATION

Data Deposition and Access

The informed consent signed by the parents protected the privacy of study participants, and such data cannot be made publicly available. The novel variant has been deposited into ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) under accession number VCV000620180.

Ethics Statement

This study was performed with Institutional Review Board (IRB) approval for Human Subjects Research at Hamad Medical Corporation and Weill Cornell Medicine-Qatar. Research participants were recruited using IRB-approved protocols and informed consents.

Acknowledgments

This work was supported by the Qatar Foundation National Priorities Research Program (NPRP11S-0110-180250).

Competing Interest Statement

The authors have declared no competing interest.
  11 in total

Review 1.  An overview and online registry of microvillus inclusion disease patients and their MYO5B mutations.

Authors:  K Joeri van der Velde; Herschel S Dhekne; Morris A Swertz; Serena Sirigu; Virginie Ropars; Petra C Vinke; Trebor Rengaw; Peter C van den Akker; Edmond H H M Rings; Anne Houdusse; Sven C D van Ijzendoorn
Journal:  Hum Mutat       Date:  2013-10-16       Impact factor: 4.878

2.  Loss-of-function of MYO5B is the main cause of microvillus inclusion disease: 15 novel mutations and a CaCo-2 RNAi cell model.

Authors:  Frank M Ruemmele; Thomas Müller; Natalia Schiefermeier; Hannes L Ebner; Silvia Lechner; Kristian Pfaller; Cornelia E Thöni; Olivier Goulet; Florence Lacaille; Jacques Schmitz; Virginie Colomb; Frédérique Sauvat; Yann Revillon; Danielle Canioni; Nicole Brousse; Genevieve de Saint-Basile; Juliette Lefebvre; Peter Heinz-Erian; Axel Enninger; Gerd Utermann; Michael W Hess; Andreas R Janecke; Lukas A Huber
Journal:  Hum Mutat       Date:  2010-05       Impact factor: 4.878

3.  Microvillus inclusion disease: an inherited defect of brush-border assembly and differentiation.

Authors:  E Cutz; J M Rhoads; B Drumm; P M Sherman; P R Durie; G G Forstner
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

4.  Microvillous inclusion disease: how to improve the prognosis of a severe congenital enterocyte disorder.

Authors:  Ugur Halac; Florence Lacaille; Francisca Joly; Jean-Pierre Hugot; Cécile Talbotec; Virginie Colomb; Frank M Ruemmele; Olivier Goulet
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-04       Impact factor: 2.839

5.  Familial microvillous atrophy: a clinicopathological survey of 23 cases.

Authors:  A D Phillips; J Schmitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  1992-05       Impact factor: 2.839

6.  MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity.

Authors:  Thomas Müller; Michael W Hess; Natalia Schiefermeier; Kristian Pfaller; Hannes L Ebner; Peter Heinz-Erian; Hannes Ponstingl; Joachim Partsch; Barbara Röllinghoff; Henrik Köhler; Thomas Berger; Henning Lenhartz; Barbara Schlenck; Roderick J Houwen; Christopher J Taylor; Heinz Zoller; Silvia Lechner; Olivier Goulet; Gerd Utermann; Frank M Ruemmele; Lukas A Huber; Andreas R Janecke
Journal:  Nat Genet       Date:  2008-08-24       Impact factor: 38.330

7.  MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease.

Authors:  Muriel Girard; Florence Lacaille; Virginie Verkarre; Raphael Mategot; Gerard Feldmann; Alain Grodet; Frédérique Sauvat; Sabine Irtan; Anne Davit-Spraul; Emmanuel Jacquemin; Frank Ruemmele; Dominique Rainteau; Olivier Goulet; Virginie Colomb; Christophe Chardot; Alexandra Henrion-Caude; Dominique Debray
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

8.  Point of Care Exome Sequencing Reveals Allelic and Phenotypic Heterogeneity Underlying Mendelian disease in Qatar.

Authors:  Khalid A Fakhro; Amal Robay; Juan L Rodrigues-Flores; Jason G Mezey; Alya A Al-Shakaki; Omar Chidiac; Dora Stadler; Joel A Malek; Abu Bakr Imam; Arwa Sheikh; Asmaa Azzam; Ibrahim Janahi; Izzat Khanjar; Kamal Osman; Maen Abu Ziki; Mohamed Adnan Mahmah; Mohamed Selim; Nuha Numeiri; Rehab Ali; Shenela Lakhani; Fizza Butt; Tawfeg Ben Omran; Ronald G Crystal
Journal:  Hum Mol Genet       Date:  2019-12-01       Impact factor: 6.150

Review 9.  Microvillous inclusion disease (microvillous atrophy).

Authors:  Frank M Ruemmele; Jacques Schmitz; Olivier Goulet
Journal:  Orphanet J Rare Dis       Date:  2006-06-26       Impact factor: 4.123

Review 10.  MYO5B, STX3, and STXBP2 mutations reveal a common disease mechanism that unifies a subset of congenital diarrheal disorders: A mutation update.

Authors:  Herschel S Dhekne; Olena Pylypenko; Arend W Overeem; Malik Zibouche; Rosaria J Ferreira; K Joeri van der Velde; Edmond H H M Rings; Carsten Posovszky; Peter van der Sluijs; Morris A Swertz; Anne Houdusse; Sven C D van IJzendoorn
Journal:  Hum Mutat       Date:  2018-01-17       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.